While GLP-1 agonists have revolutionized obesity treatment, a significant challenge remains: the "ceiling effect" and the substantial population of patients who do not respond adequately to current therapies. The next frontier in metabolic medicine lies in looking deeper beyond the receptor and into the complex mitochondrial signaling networks that drive cellular metabolism and energy expenditure.

At Elucidata, we are bridging the gap between mitochondrial biology and therapeutic discovery. By harmonizing complex metabolomics and multi-omics data, we empower researchers to identify novel metabolic checkpoints and validate targets that go beyond the standard GLP-1 pathways. Our platform, Polly, turns messy, high-dimensional metabolic data into a structured asset, enabling the design of precision medicines for patients with resistant obesity phenotypes.

Join our team of experts, Vaibhav Mittal and Sachin Kumar Gupta, along with our Scientific Co-Founder and Yale Assistant Professor, Dr. Richard Kibbey, as we engage with leading obesity researchers. We will be discussing how a data-centric approach is unlocking new strategies to treat metabolic disorders and address the critical unmet needs in the post-GLP-1 era.

‍